The Deal
Sunday, November 8, 
1:41 pm

IPO pile up

  Share     E-Mail    Discussion    Print Story

The number of venture-backed life sciences companies unwilling to take the plunge into the frigid IPO waters grew on Monday, as both Asthmatx Inc. and BioVex opted to postpone their offerings. Cancer treatment biotech company BioVex cited unfavorable market conditions; while Asthema medical device maker Asthmatx said it was withdrawing its IPO in favor of an alternative strategic option.

While their have been some real home runs recently by IT offering such as DivX Inc., CommVault Inc. and Riverbed Technology Inc., life sciences IPOs have been a hard slog. The few to make it out the IPO door this fall - Ivivi Technologies Trubion Pharmaceuticals Inc. and LeMaitre Vascular - all had lackluster debuts as Trubion and Ivivi have traded relatively flat, and LeMaitre is currently below its offering price.

Nevertheless, life sciences companies have continued to line up at the IPO door in the hope that some holiday cheer will soften things up, as three more life sciences companies - Cadence Pharmaceuticals, Achillion Pharmaceuticals, and Catalyst Pharmaceutical Partners - are all slated to price this week according to Renaissance Capital LLC's IPOHome.com. — George White

Continue reading below

Also on Dealscape





Post a comment




The Deal Pipeline

Deal Video


Inside The Deal: Linklaters' Schmidt says how regulators handled Pfizer Inc.'s acquisition of Wyeth is an outlier of how others merger reviews will be conducted.


More video...

Crisis On Wall Street
Technology
Deals of The Decade

Community

Industry Insight

Dealing with frozen bank lending

If your bank is not willing to lend, what can you do as your company continues to seek growth?


Judgment Call

The coming age of the renminbi

The Chinese currency will play an increasingly important role in international commerce and finance.


Industry Insight

Banking on PE investments

Howls of protest greeted the FDIC policy statement, but the financial services industry should get over it.



©Copyright 2008, The Deal, LLC. All rights reserved. Please send all technical questions, comments or concerns to the Webmaster.